Jubilant Life shares fall on US FDA warning letter

Wed Feb 27, 2013 2:52pm IST

Related Topics

Stocks

   

REUTERS - Shares in Jubilant Life Sciences Ltd (JULS.NS) fell as much as 6.9 percent on Wednesday after U.S. health regulators issued a warning letter to the company, citing "significant violations" of manufacturing standards at its facility in Canada.

The U.S. Food and Drug Administration may hold drug approvals until Jubilant HollisterStier General Partnership takes necessary corrective steps, Jubilant said in a statement.

Other bigger Indian companies such as Dr. Reddy's Laboratories Ltd (REDY.NS), Ranbaxy Laboratories Ltd (RANB.NS), Sun Pharmaceutical Industries Ltd (SUN.NS) and Aurobindo Pharma (ARBN.NS) have all received regulatory warning letters on compliance over the last four years.

The company said its on-going manufacturing, distribution and sale of products would not be affected by the warning letter, and it plans to respond to the drug regulator on or before March 15.

Shares in Jubilant Life Sciences, which has a market value of about $548.5 million, fell 4.25 percent to 178 rupees. They earlier touched a low of 173 rupees. The Sensex was up 0.67 percent.

(Reporting by Kaustubh Kulkarni in Mumbai; Editing by Anand Basu)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Economic Pulse

Economic Pulse

New govt promises low and stable tax regime for economic revival.  Full Article 

Global Growth

Global Growth

IMF cuts outlook, warns of stagnation risk in rich nations  Full Article 

Market Eye

Market Eye

Nifty retreats from record highs on profit taking.  Full Article 

Waning Enthusiasm

Waning Enthusiasm

Markets' post-election enthusiasm lost on consumers.  Full Article 

Banking Sector

Banking Sector

Banks not allowed to trade in bonds for infra lending - RBI.  Full Article 

Gold Imports

Gold Imports

Govt has no proposal to reduce gold import duty.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage